Curacle Co

Curacle Co R&D per Employee

The R&D Spending per Employee of Curacle Co (365270.KQ) as of Oct 16, 2026 is 96.95 M KRW. In the previous year, R&D Spending per Employee was 17.35 M KRW — a change of 458.75% (higher).

R&D per Employee

96.95 MKRW

YoY

458.75%

Last updated:

R&D Spending per Employee of Curacle Co is 2022 96.95 M KRW. R&D Spending per Employee of Curacle Co was 2021 17.35 M KRW. It decreases by 458.75% higher compared to the previous year.

The Curacle Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
120.50 M KRW
Jan 1, 2020
178.26 M KRW
Jan 1, 2021
17.35 M KRW
Jan 1, 2022
96.95 M KRW
The Curacle Co R&D per Employee history
YEARR&D per EmployeeYoY
96.95 MKRW+458.75%
17.35 MKRW-90.27%
178.26 MKRW+47.93%
120.50 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curacle Co Stock analysis

What does Curacle Co do? Curacle Co Ltd is a biotechnology company based in Seoul, South Korea, operating within the healthcare sector. The company focuses on research and experimental development in medical sciences and pharmacy, with a specific emphasis on developing treatments for intractable vascular diseases. As of the latest available information, Curacle employs 35 full-time staff members. The company completed its initial public offering (IPO) on July 22, 2021. Curacle is developing synthetic drugs including CU06-RE, CU01, and a natural drug referred to as CU03, which are targeted at conditions such as diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). The company utilizes a platform technology known as SOLVADYS, designed for the development of vascular endothelial dysfunction blockers. Curacle's website is http://www.curacle.com, providing further details about its research and development activities. The company's operations are centered around innovative drug development aimed at addressing significant unmet medical needs in vascular disease treatment. No additional details about founding year, specific executives, or financial figures beyond the IPO date are provided in the available information. Curacle Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curacle Co stock

R&D Spending per Employee of Curacle Co is 96.95 M KRW in 2022.

R&D Spending per Employee of Curacle Co changed from 17.35 M KRW to 96.95 M KRW, representing a 458.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Curacle Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Curacle Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Curacle Co

All Key Metrics — Curacle Co